Full-Time
Senior Project Engineer Instruments
Brainlab
1,001-5,000 employees
Medical software and hardware for surgeries
No salary listed
Munich, Germany
Hybrid
Hybrid work model within Germany.
 Biology & Biotech (1) |
|---|
- A degree from higher education in the respective field and 5 years of professional experience
- Experience with technical documentation for medical devices under MDR
- Analytical mindset and creativity to develop reliable solutions
- A well-organized and clearly structured work style
- Good communication skills in general
- Fluent written and spoken English
- Establish requirements, ensure that the underlying clinical rationale and supporting literature are documented, and identify any conflicting or shared requirements across teams and projects
- Engage actively in agile development sprints and proactively ensure that concept-related risks are clearly understood and managed
- Conduct literature searches and collaborate with Clinical Affairs and the use-case owner to prepare clinical documentation
- Definition, coordination and/or execution of verification tests of medical devices
- Creation of technical documentation acc. to international (MDR, FDA) and company standards
- Collaborate and communicate with other R&D departments, manufacturers, and internal teams such as QM, QA, Usability, Purchasing, and Legal
- Ideally experience with research of clinical literature in databases such as Embase and Medline and knowledge of surgical instruments and use
Brainlab is a medical technology company that creates software and hardware to improve surgeries, radiosurgery treatments, and operating room efficiency. It serves hospitals and clinics by providing digital tools that enhance surgical precision and patient outcomes. The core products include image-guided navigation, planning software, and connected hardware that work together to guide procedures. Revenue comes from selling software licenses, hardware devices, and ongoing subscription services that include updates and support. The company differentiates itself by offering integrated digital medical technologies that combine software and hardware for a seamless clinical workflow, backed by service agreements. Its goal is to help healthcare providers perform safer, more accurate procedures and run operating rooms more efficiently through data-driven tools and ongoing support.
Company Size
1,001-5,000
Company Stage
Early VC
Total Funding
$7.3M
Headquarters
Munich, Germany
Founded
1989
Simplify's Take
What believers are saying
- Record €239M H1 FY2024/25 revenues with 22.4% EBITDA margin demonstrate operational efficiency.
- Mid-term 10-13% revenue growth targets supported by strong profitability trajectory and market expansion.
- European digital health infrastructure investment in AB S.A. positions Brainlab for subscription-based growth.
What critics are saying
- Postponed Frankfurt IPO restricts €200M capital access, stalling commercialization and clinical expansion.
- Medtronic StealthStation S8 and Mazor X systems capture 25% larger US neurosurgery market share.
- Stryker Mako robotic system dominates orthopedic navigation with 40% penetration, undercutting Brainlab hardware sales.
What makes Brainlab unique
- FDA-cleared mixed reality spine navigation system differentiates Brainlab's surgical guidance capabilities.
- Strategic AI partnership with Precision NeuroMed expands addressable market into neurodegenerative diseases.
- Federal VA and DoD contracts via Lovell expand Brainlab's government healthcare footprint significantly.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Brainlab who can refer or advise you
Benefits
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Conference Attendance Budget
Professional Development Budget
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Health Insurance
Company News
Brainlab and Precision NeuroMed have formed a strategic partnership to develop an AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain. Brainlab has taken an equity stake in the clinical-stage biotechnology company as part of the collaboration. The partnership aims to create a cloud-based CED Treatment Planning System that combines Brainlab's medical imaging expertise with Precision NeuroMed's molecular flow simulation software. The platform will use advanced imaging and AI-driven optimisation to personalise drug distribution, overcoming blood-brain barrier limitations that restrict most systemically administered drugs. Initial development will focus on supporting Precision NeuroMed's lead drug, PNM-201, for recurrent glioblastoma. The companies plan to expand the platform to enable delivery of therapies for epilepsy, Parkinson's disease, Alzheimer's disease and ALS.
Lovell Government Services, a Service-Disabled Veteran-Owned Small Business, has been awarded a Patient Monitoring and Capital Equipment contract with Brainlab, expanding access to advanced surgical technology across VA and DoD facilities. The partnership adds capital equipment and patient monitoring solutions to Lovell's federal portfolio, which previously focused on consumables. Brainlab, a digital medical technology company operating in 4,000 hospitals across 120 countries, first partnered with Lovell in 2024. The company develops integrated hardware and software for surgery and radiation therapy. The contract builds on Lovell's strong 2025 performance, which included over $100 million in sales, expanded Defence Logistics Agency Electronic Catalog access, and pharmaceutical distribution accreditation. Founded in 2013, Lovell has appeared four times on the Inc. 5000 list.
Brainlab has received FDA 510(k) clearance and launched its Spine Mixed Reality Navigation system in the United States.
Medtech firm Brainlab has decided to postpone its planned initial public offering (IPO) in Frankfurt, which was expected to raise $378 million.
Brainlab AG is launching an IPO on the Frankfurt Stock Exchange to raise up to €200 million, aiming to enhance its digital healthcare ecosystem. The company reported record revenues of €239 million and a 22.4% EBITDA margin in the first half of FY 2024/25. The IPO proceeds will support commercialization, expansion into new clinical applications, and balance sheet strengthening. Brainlab targets mid-term revenue growth of 10-13% and an EBITDA margin in the mid-20s, with a long-term goal of up to 30%.